Huo KL, Yang TY, Zhang WW, Shao J. Mesenchymal stem/stromal cells-derived exosomes for osteoporosis treatment. World J Stem Cells 2023; 15(3): 83-89 [PMID: 37007454 DOI: 10.4252/wjsc.v15.i3.83]
Corresponding Author of This Article
Jin Shao, MD, PhD, Associate Professor, Deputy Director, Department of Orthopedics, Pudong New Area Gongli Hospital, School of Medical Technology, University of Shanghai for Science and Technology, No. 219 Miaopu Road, Pudong New Area, Shanghai 200135, China. shaojin_1977@126.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Mar 26, 2023; 15(3): 83-89 Published online Mar 26, 2023. doi: 10.4252/wjsc.v15.i3.83
Mesenchymal stem/stromal cells-derived exosomes for osteoporosis treatment
Kai-Lun Huo, Tie-Yi Yang, Wei-Wei Zhang, Jin Shao
Kai-Lun Huo, Postgraduate Training Base in Shanghai Gongli Hospital, Ningxia Medical University, Yinchuan 750004, the Ningxia Hui Autonomous Region, China
Tie-Yi Yang, Jin Shao, Department of Orthopedics, Pudong New Area Gongli Hospital, School of Medical Technology, University of Shanghai for Science and Technology, Shanghai 200135, China
Wei-Wei Zhang, Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Author contributions: Shao J and Zhang WW were responsible for the concept design; Huo KL, Shao J and Zhang WW wrote the main manuscript text and prepared Figures 1 and 2; Yang TY provided technical support; all authors reviewed the manuscript.
Supported byNational Natural Science Foundation of China, No. 81703533; Natural Science Foundation of Shanghai, No. 20ZR1449500; Shanghai Jiao Tong University Medical Engineering Cross Fund, No. YG2019GD02; Science Technology Development Fund of Shanghai Pudong New Area, No. PKJ2020-Y28; and Medical Discipline Construction Project of Pudong Health Committee of Shanghai, No. PWYts2021-05.
Conflict-of-interest statement: The authors declare no conflict of interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jin Shao, MD, PhD, Associate Professor, Deputy Director, Department of Orthopedics, Pudong New Area Gongli Hospital, School of Medical Technology, University of Shanghai for Science and Technology, No. 219 Miaopu Road, Pudong New Area, Shanghai 200135, China. shaojin_1977@126.com
Received: December 26, 2022 Peer-review started: December 26, 2022 First decision: January 3, 2023 Revised: January 17, 2023 Accepted: March 16, 2023 Article in press: March 16, 2023 Published online: March 26, 2023 Processing time: 87 Days and 1.5 Hours
Abstract
Osteoporosis is a systemic bone disease, which leads to decreased bone mass and an increased risk of fragility fractures. Currently, there are many anti-resorption drugs and osteosynthesis drugs, which are effective in the treatment of osteoporosis, but their usage is limited due to their contraindications and side effects. In regenerative medicine, the unique repair ability of mesenchymal stem cells (MSCs) has been favored by researchers. The exosomes secreted by MSCs have signal transduction and molecular delivery mechanisms, which may have therapeutic effects. In this review, we describe the regulatory effects of MSCs-derived exosomes on osteoclasts, osteoblasts, and bone immunity. We aim to summarize the preclinical studies of exosome therapy in osteoporosis. Furthermore, we speculate that exosome therapy can be a future direction to improve bone health.
Core Tip: Osteoporosis is one of the major diseases endangering bone health in the elderly. The existing treatment drugs have problems such as long-term administration and side effects; thus, it is fundamentally difficult to cure osteoporosis. Exosomes derived from mesenchymal stem cells (MSCs) are vesicles that deliver signals and molecules between cells and have shown substantial positive effects in pre-clinical trials. In this review, we summarize the latest progress of MSCs-derived exosomes in the regulation of bone metabolism.
